Abstract: A turntable includes a rotatably supported table, an electric cylinder, and a cam mechanism configured to convert the linear motion of the electric cylinder into the rotary motion of the table. The cam mechanism includes at least one cam groove provided on the table side, and at least one cam follower moved in parallel to the linear motion direction of the electric cylinder and configured to engage with the at least one cam groove.

Abstract: A turntable includes a rotatably supported table, an electric cylinder, and a cam mechanism configured to convert the linear motion of the electric cylinder into the rotary motion of the table. The cam mechanism includes at least one cam groove provided on the table side, and at least one cam follower moved in parallel to the linear motion direction of the electric cylinder and configured to engage with the at least one cam groove.

Abstract: The invention relates to pyroglutamic acid esters used as dermal penetration enhancers for therapeutic agents having poor skin permeation.

Abstract: The invention relates to pyroglutamic acid esters used as dermal penetration enhancers for therapeutic agents having poor skin permeation.

Abstract: There is provided a fluorescent adduct which is amenable to detection by fluorometric and electrochemical techniques. The adduct is of the formula: ##STR1## wherein X is a radical derived from a primary amine of the formula X--NH.sub.2 and where R.sub.1 --R.sub.6 are selected from various organic or inorganic substituents.

Abstract: The invention relates to pyroglutamic acid esters used as dermal penetration enhancers for therapeutic agents having poor skin permeation.

Abstract: A compound having the formula: ##STR1## wherein R, R.sub.1 and R.sub.2 are independently selected from hydrogen; hydroxy; fluorine; bromine; chlorine; C.sub.1 -C.sub.20 alkyl; C.sub.2 -C.sub.20 alkenyl; C.sub.2 -C.sub.20 alkynyl; C.sub.3 -C.sub.10 cycloalkyl; C.sub.2 -C.sub.20 (monohydroxy or polyhydroxy)alkyl; C.sub.1 -C.sub.20 (monohalo or polyhalo)alkyl; carboxy; C.sub.1 -C.sub.20 alkylcarboxy; C.sub.1 -C.sub.20 alkenylcarboxy; C.sub.1 -C.sub.20 carboxyalkyl; C.sub.1 -C.sub.20 alkanoyl; C.sub.1 -C.sub.20 alkanoyloxy; C.sub.1 -C.sub.20 alkoxycarbonyl; carbamoyl; carbamyl; C.sub.1 -C.sub.20 alkylcarbamyl; sulfo; C.sub.1 -C.sub.20 alkylsulfonyl; C.sub.1 -C.sub.20 alkylsulfinyl; C.sub.1 -C.sub.20 alkylsulfoxide; C.sub.1 -C.sub.20 alkylsulfone; thio; C.sub.1 -C.sub.20 alkylthio; amino; nitro; C.sub.1 -C.sub.20 alkylamino; C.sub.1 -C.sub.20 aminoalkyl; substituted or unsubstituted phenyl or benzyl, the substituents being selected from hydroxy, fluorine, bromine, chlorine, C.sub.1 -C.sub.20 alkyl, C.sub.2 -C.sub.

Abstract: A method of assaying primary amines or cyanide is disclosed. The process is carried out by reacting a substituted or unsubstituted naphthalene-2,3-dicarboxaldehyde or o-phthalaldehyde, reactive with primary amines and cyanide, with cyanide ions and at least one primary amine to form an adduct amenable to fluorometric or electrochemical assaying techniques. The adduct is then fluorometrically or electrochemically assayed.Also disclosed are 1-cyano-benz[f]isoindole adducts.

Abstract: Provided is a novel barrier membrane and a method using the barrier membrane for testing the transdermal penetration behavior of a bioactive agent. The method employs shed snake skin as the model barrier membrane. In particular, the method comprises the steps of providing a dose of a donor formulation containing the bioactive agent, and a receptor solution, with a barrier membrane of shed snake skin separating the donor formulation and receptor solution. The receptor solution is then serially sampled and assayed in order to determine the concentration of the bioactive agent in the receptor solution. The use of the shed snake skin has been found to provide reproducible and uniform results as a model barrier membrane. As well, the shed snake skin offers the advantages of being readily available and storable for an extended period of time.

Abstract: The invention relates to pyroglutamic acid esters used as dermal penetration enhancers for therapeutic agents having poor skin permeation.

Abstract: A drug delivery device retained in the stomach comprising a ring figure made from polymer(s) that may release a drug associated therewith over a controlled, predictable and extended period of time.

Abstract: A chemiluminescence method for assaying compounds containing primary amino groups using 1-cyano-2-substituted benz(f)- or naphth(f)-isoindole fluorescers is disclosed. The 1-cyano-2-substituted benz(f)- or naphth(f)-isoindole (CBI or CNI) is formed by reacting a compound containing a primary amino group with naphthalene-2-3-dicarboxaldehyde or anthracene-2,3-dicarboxaldehyde in the presence of cyanide ion. The reaction product of hydrogen peroxide with an oxalate ester is then combined with the CBI or CNI to form an analyte which exhibits chemiluminescence. A detector is used to measure the chemiluminescence emission from the chemiluminescence derivatized analytes. Compounds containing primary amino groups which may be assayed according to the present invention include primary amines, amino acids, peptides and catecholamines. The method can also be adapted to the analysis of trace amounts of cyanide ion and hydrogen peroxide.

Abstract: A diffusion cell for use in determining the absorption rate of a study substance through a permeable membrane. The cell includes a receptor chamber which contains receptor fluid to receive study substance absorbed through the membrane. The receptor chamber includes a fluid inlet and a fluid outlet. A rotary stirrer is situated adjacent the fluid outlet. The stirrer is rotated so as to rotate the receptor fluid in the receptor chamber in such manner that the fluid pressure is greater at the outlet than at the inlet, so that the stirrer defines a pump which pumps receptor fluid outwardly through the outlet, then through a detector, and then back into the receptor chamber through the inlet. The detector determines the concentration of study substance within the receptor fluid.

Abstract: A new class of substituted 2,3-naphthalenedicarboxaldehydes (NDA) is disclosed. Such compounds are of the formula: ##STR1## wherein one or more of R.sub.1 -R.sub.8 are various substituting groups. The above compounds react, in the presence of cyanide ion, with compounds containing primary amino groups to form adducts which exhibit a high fluorescent yield and thus are readily detected and measured by fluorometric assaying techniques.

Abstract: The instant invention is directed to a lipid osmotic pump, comprising:(A) a core, comprising:(i) a beneficial amount of at least one substantially water insoluble active agent which is lipid soluble and/or lipid wettable;(ii) a sufficient amount of at least one water immiscible lipid carrier, which is liquid at the temperature of intended use, to dissolve and/or suspend said active agent; and(iii) a sufficient amount of at least one osmotic agent to ensure release of said lipid carrier from the pump; and(B) surrounded by a water insoluble wall:(i) having a thickness of about 1 to 1000 microns;(ii) which is preferentially wetted by said lipid carrier over an aqueous solution of said osmotic agent;(iii) having a water permeability of about 1.times.10.sup.-18 to 4.times.10.sup.-15 cm.sup.

Abstract: Certain novel cyclic ureas are disclosed herein as dermal penetration enhancers of drug absorption. Also disclosed herein are compositions, methods of treatment and processes for preparing said cyclic urea compounds.

Abstract: The invention relates to the use of an acid anhydride incorporated as a latentiated catalyst in poly(ortho ester) and other polymers such that upon exposure to aqueous environments the acid anhydride generates the corresponding acid which catalyzes the matrix erosion. The releasing rate of a loaded drug substance incorporated into or surrounded by the poly(ortho ester) or other polymers can be controlled in that the drug is released as the poly(ortho ester)s or other polymer is eroded by action of the acid anhydride incorporated therein.

Abstract: This invention relates to a unique drug delivery system for delivering drugs to a body cavity. The drug delivery system comprises a medicament and a polymer such that the drug delivery system is a liquid at room temperature but forms a semi-solid or gel at the body temperature in the body cavity.

Abstract: Present invention provides a unique drug delivery device for delivering drug by injection into a body. The drug delivery system comprises the drug and polymer which is a liquid at room temperature and a semi-solid or gel at the body temperature.

Abstract: This invention describes the application of selected polymers as novel drug delivery systems which use the body temperature and pH to induce a liquid to gel transition of the polymer which contains a drug or therapeutic agent therein. The goal of such a delivery system is to achieve a greater degree of bioavailability or sustained concentration of a drug.